Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoMono neoadjuvant atezolizumab window trial in triple-negative breast cancer
2020-001651-40Phase 2Completed
- Sponsor
- Palleos Healthcare
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Palleos Healthcare. Primary endpoint: Pathologic complete response. Started Aug 2020; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2020-001651-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001651-40.